Ketone supplements for treatment of angelman syndrome
AssigneeUniversity of South Florida
InventorsEDWIN JOHN WEEBER, STEPHANIE LYNN CIARLONE, DOMINIC PAUL D'AGOSTINO
Life of this patent
Estimating the term…
Abstract
The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.
Claims16
1-15. (canceled)
A method of treating Angelman Syndrome (AS) in a subject, comprising administering a ketone supplement to the subject.
A method of increasing cognitive function and/or motor function in a subject with Angelman Syndrome (AS), comprising administering a ketone supplement to the subject.
A method of decreasing seizures, increasing the latency to seize, and/or increasing the ratio of hippocampal gamma-amino butyric acid (GABA) to glutamate in a subject with Angelman Syndrome (AS), comprising inducing ketosis in the subject by administering a ketone supplement.
Dependencies are inferred from the claim text.